DOCSLIB.ORG

ICU Resident's Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICU Resident's Guide SOCIETY OF CRITICAL CARE ANESTHESIOLOGISTS ICU Resident’s Guide 2017 Welcome to critical care. Whether you are using this review guide for your first Foreword rotation in critical care or your tenth, we hope that you find it useful as a supplement to the other reading materials at your disposal. The delivery of critical care continues to change rapidly. Therapies that were deemed beneficial in the past (drotrecogin alfa, tight glucose control, etc) are now considered harmful, so it’s difficult to keep up-to-date with textbooks alone. Our goal is to provide concise clinically relevant chapters that are useful for the trainee working in the ICU. Each chapter’s relevance is illustrated with a sample case and the concepts are then reviewed with self-test multiple choice questions. Further in depth learning can be obtained with the selected reference list at the end of each chapter. For those who grew up with digital media, we have also tried to incorporate new technologies by adding videos, hyperlinks, and interactivity. Finally, we would like to give our heartfelt gratitude to the many trainees and faculty mentors across the nation who have contributed to this edition or past editions. Without their help and expertise, we would have never succeeded. Thank you to the prior editors as well, for without their vision, we would not be here with the sixth edition. Best wishes to the newcomers. May you enjoy the field as much as we have. Lindsey L. Huddleston, MD Linda L. Liu, MD Kevin C. Thornton, MD i Section 1 Contributors Eric Amaro, MD Stephanie Cha, MD University of Miami Miller School of Medicine The Johns Hopkins Hospital Department of Anesthesiology Department of Anesthesiology and Critical Care Medicine Fellow Assistant Professor Ruben J Azocar, MD MHCM FCCM Nisha Chhabra, MD Tufts Medical Center University of Chicago Medical Center Department of Anesthesiology Department of Anesthesia and Critical Care Associate Professor Fellow Edward A Bittner, MD PhD MSEd Anoop K Chhina, MD MBBS Massachusetts General Hospital Cleveland Clinic Department of Anesthesia, Critical Care and Pain Medicine Department of Anesthesiology and Pain Management Assistant Professor Fellow Jason C Brainard, MD Kathleen Claus, MD University of Colorado School of Medicine Tufts Medical Center Department of Anesthesiology Department of Anesthesiology Assistant Professor Assistant Professor Guarav Budhrani, MD Elizabeth KH Cotter, MD Emory University School of Medicine University of Chicago Medical Center Division of Critical Care Medicine Department of Anesthesia and Critical Care Assistant Professor Fellow 2 Aaron Dahl, MD Albert W Feng, MD Washington University David Geffen School of Medicine at UCLA Department of Anesthesiology Department of Anesthesiology and Perioperative Medicine Fellow Resident Murtaza Diwan, MD Natalie Ferrero, MD University of Michigan University of Michigan Department of Anesthesiology, Division of Critical Care Medicine Department of Anesthesiology, Division of Critical Care Medicine Clinical Lecturer Resident Anila B. Elliott, MD Babar Fiza, MD Oregon Health & Science University University of Michigan Department of Anesthesiology and Perioperative Medicine Department of Anesthesiology, Division of Critical Care Medicine Fellow Clinical Lecturer Katie M Ellis, MD Alexander C Fort, MD Portland VA Healthcare System University of Miami Miller School of Medicine Critical Care Anesthesiologist Department of Anesthesiology Assistant Professor Assistant Professor Kelly K Everhart, MD MS Samuel Gilliland, MD University of Washington/Harborview Medical Center University of Colorado School of Medicine Department of Anesthesiology and Pain Medicine Department of Anesthesiology Resident Assistant Professor Brenda G Fahy, MD Thomas J Graetz, MD University of Florida Washington University Department of Anesthesiology Department of Anesthesiology Professor Assistant Professor 3 Caroline Gross, MD Ryan J Horvath, MD PhD College of Physicians & Surgeons, Columbia University Massachusetts General Hospital Department of Anesthesiology Department of Anesthesia, Critical Care and Pain Medicine Resident Fellow Holden Groves, MD Leila Hosseinian, MD College of Physicians & Surgeon, Columbia University Mount Sinai Medical Center Department of Anesthesiology Department of Anesthesiology Resident Assistant Professor Vadim Gudzenko, MD Walter J Hoyt, MD David Geffen School of Medicine at UCLA University of Virginia Department of Anesthesiology and Perioperative Medicine Department Cardiology Assistant Professor Fellow J Michael Guthrie, MD John Huidekoper, MD David Geffen School of Medicine at UCLA University of Alabama Birmingham Hospital Department of Anesthesiology and Perioperative Medicine Department of Anesthesiology and Perioperative Medicine Fellow Fellow Theresa L Hartsell, MD PhD Jose C Humanez, MD The Johns Hopkins University University of Alabama Birmingham Hospital Department of Anesthesiology and Critical Care Medicine Department of Anesthesiology and Perioperative Medicine Assistant Professor Assistant Professor C Patrick Henson, DO Michael Hutchens, MD Vanderbilt University Oregon Health and Science University Department of Anesthesiology, Division of Critical Care Department of Anesthesiology and Perioperative Medicine Assistant Professor Associate Professor 4 Rhea Ittoop, MD Jeffrey A Katz, MD College of Physicians & Surgeons, Columbia University Northshore University Department of Anesthesiology Department of Anesthesia and Critical Care Resident Attending Physician Thomas Jan, MD MPH John C Klick, MD Mount Sinai Medical Center Case Western Reserve University School of Medicine Department of Anesthesiology Department of Anesthesiology and Perioperative Medicine Fellow Assistant Professor Allison M Janda, MD Matthew D Koff, MD Vanderbilt University Medical Center Geisel School of Medicine, Dartmouth-Hitchcock Medical Center Department of Anesthesiology, Division of Critical Care Department of Anesthesiology Resident Assistant Professor Aaron M Joffe, DO FCCM Michael R Lasky, MD University of Washington/Harborview Medical Center Saint Louis University Hospital Department of Anesthesiology and Pain Medicine Department of Anesthesiology and Critical Care Associate Professor Associate Professor Maurice F Joyce, MD EdM Stuart Lowson, MD Massachusetts General Hospital University of Virginia Department of Anesthesia, Critical Care and Pain Medicine Department of Anesthesiology Fellow Associate Professor Aalok K Kacha, MD PhD Elvedin Lukovic, MD University of Chicago Medical Center College of Physicians & Surgeons, Columbia University Department of Anesthesia and Critical Care Department of Anesthesiology Assistant Professor Resident 5 Michael Maile, MD Lydia Miller, MD University of Michigan Massachusetts General Hospital Department of Anesthesiology, Division of Critical Care Medicine Department of Anesthesia, Critical Care and Pain Medicine Assistant Professor Resident Darren J Malinoski, MD Teresa A Mulaikal, MD Oregon Health and Science University College of Physicians & Surgeons, Columbia University Department of Surgery Department of Anesthesiology Associate Professor Assistant Professor Sarah McCormick, MD Douglas F Naylor, MD FACS MCCM University of Alabama Birmingham Hospital Cleveland Clinic Department of Anesthesiology and Perioperative Medicine Department of Anesthesiology and Pain Medicine Fellow Staff Intensivist Tracy J McGrane, MD Christopher O Ortiz, MD PhD Vanderbilt University Medical Center David Geffen School of Medicine at UCLA Department of Anesthesiology, Division of Critical Care Department of Anesthesiology and Perioperative Medicine Assistant Professor Assistant Professor Joseph Meltzer, MD Jamel P Ortoleva, MD David Geffen School of Medicine at UCLA Massachusetts General Hospital Department of Anesthesiology and Perioperative Medicine Department of Anesthesia, Critical Care and Pain Medicine Associate Professor Fellow David W Miller, MD David B Page, MD University of Alabama Birmingham Hospital Washington University Department of Anesthesiology and Perioperative Medicine Department of Anesthesiology Associate Professor Fellow 6 Ryan Parker, MD PhD Amanda Powers, MD Vanderbilt University Medical Center College of Physicians & Surgeons, Columbia University Department of Anesthesiology, Division of Critical Care Department of Anesthesiology Assistant Professor Assistant Professor Mona K Patel, PharmD Meghan Prin, MD NewYork-Presbyterian Hospital College of Physicians & Surgeons, Columbia University Columbia University Medical Center Department of Anesthesiology Department of Pharmacy Fulbright Fellow Critical Care Clinical Pharmacist Rahul Raghavan, MD Rohit P Patel, MD The Johns Hopkins University University of Florida Department of Anesthesiology and Critical Care Medicine Department of Anesthesiology Fellow Assistant Professor Sirisha Rao, MD Ronald Pauldine, MD David Geffen School of Medicine at UCLA University of Washington Department of Anesthesiology and Perioperative Medicine Department of Anesthesiology and Pain Medicine Fellow Professor Matthew M Reschke, MD Nicholas Pesa, MD Saint Louis University Hospital University Hospitals Case Medical Center Department of Anesthesiology and Critical Care Department of Anesthesiology Resident Clinical Instructor Lauren D Rosenberg, MD Julia C Peters, MD MA College of Physicians & Surgeons, Columbia University Geisel School of Medicine, Dartmouth-Hitchcock Medical Center Department of Anesthesiology Department of Anesthesiology Resident Fellow 7 Daniel Rubin, MD Philip Sommer, MD University
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Spring 2009 Student Journal
    Volume 8 Number 1 Spring 2009 The International Student Journal of Nurse Anesthesia TOPICS IN THIS ISSUE MS & ECT Cardioprotection of Volatile Agents Hyperthermic Chemotherapy Intubating LMA Pierre Robin Syndrome Alpha Thalassemia Latex Allergy & Spina Bifida Distorted Upper Airway Volunteerism – Honduras INTERNATIONAL STUDENT JOURNAL OF NURSE ANESTHESIA Vol. 8 No. 1 Spring 2009 Editor - in - Chief Ronald L. Van Nest, CRNA, JD Associate Editors Vicki C. Coopmans, CRNA, PhD Julie A. Pearson, CRNA, PhD EDITORIAL BOARD & SECTION EDITORS Pediatrics Janet A. Dewan, CRNA, MS Northeastern University Obstetrics Greg Nezat, CRNA, PhD Navy Nurse Corps Anesthesia Program Research & Capstone Joseph E. Pellegrini, CRNA, University of Maryland PhD Regional / Pain Christopher Oudekerk, CRNA, Uniformed Services Universi- DNP ty of the Health Sciences Cardiovascular Michele Gold, CRNA, PhD University of Southern Cali- fornia Thoracic/ Fluid Balance Lori Ann Winner, CRNA, MSN University of Pennsylvania Unique Patient Syndromes Kathleen R. Wren, CRNA, PhD Florida Hospital College of Health Sciences Equipment Carrie C. Bowman Dalley, Georgetown University CRNA, MS Pharmacology Maria Magro, CRNA, MS, University of Pennsylvania MSN Pathophysiology JoAnn Platko, CRNA, MSN University of Scranton Special Surgical Techniques Russell Lynn, CRNA, MSN University of Pennsylvania 1 Airway & Respiration Michael Rieker, CRNA, DNP Wake Forest University Baptist Medical Center ,Nurse Anesthesia Program, Univer- sity of North Carolina at Greensboro Neurology & Neurosurgery
    [Show full text]
  • Drotrecogin Alfa (Activated)
    PRODUCT MONOGRAPH PrXIGRIS® drotrecogin alfa (activated) Sterile Powder for Intravenous Injection 5 mg or 20 mg drotrecogin alfa (activated) per vial Antithrombotic Profibrinolytic Anti-Inflammatory Enzyme © ELI LILLY CANADA INC. Date of Approval: 3650 Danforth Avenue August 20, 2009 Toronto, Ontario M1N 2E8 1-888-545-5972 www.lilly.ca Submission Control No: 128989 XIGRIS [drotrecogin alfa (activated)] Page 1 of 36 Product Monograph Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS................................................................................. 4 ADVERSE REACTIONS................................................................................................... 8 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 13 OVERDOSAGE ............................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 16 STORAGE
    [Show full text]
  • Standards for the Diagnosis and Treatment of Patients with COPD
    Copyright #ERSJournals Ltd 2004 EurRespir J 2004;23: 932– 946 EuropeanRespiratory Journal DOI: 10.1183/09031936.04.00014304 ISSN0903-1936 Printedin UK –allrights reserved ATS/ ERSTASK FORCE Standardsfor the diagnosisand treatment of patientswith COPD: asummaryof the ATS/ERSposition paper B.R. Celli*, W. MacNee*,andcommittee members Committeemembers: A Agusti, A Anzueto, B Berg, A S Buist, P M A Calverley, N Chavannes, T Dillard, B Fahy, A Fein, J Heffner, S Lareau, P Meek, F Martinez, W McNicholas, J Muris, E Austegard, R Pauwels, S Rennard, A Rossi, N Siafakas, B Tiep, J Vestbo, E Wouters, R ZuWallack *P ulmonaryand Critical C are D ivision, St Elizabeth s’ Medical Center, Tufts U niversity School of Medicine, Boston, Massachusetts, USA # Respiratory Medicine ELE GI, Colt R esearch Lab Wilkie Building, CONTEMedical Schoo l, T eviot Place, Edinburgh, UK CONTENTSNTS Background. ............................ 932 Managementof stab eCOPD:surgery in and for Goals and objectives 933 COPD.. ............................... 938 Participants 933 Surgery in COPD 938 Evidence, methodology and validation 933 Surgery for COPD 938 Concept of a "live",modular document 933 Managementof stab e COPD: s eep. ........... 938 Organisation of the document 933 Managementof stab eCOPD:air-trave . 939 De® nitionof COPD. ...................... 933 Exacerbationof COPD: de® nition, eva uation and Diagnosisof COPD. ...................... 933 treatment ............................... 939 Epidemio ogy,risk factors andnatura history De® nition 939 ofCOPD ............................... 934 Assessment 940 Patho ogyand pathophysio ogyin COPD . ....... 934 Indication for hospitalisation 940 C inica assessment, testingand differentia diagnosisof Indications for admission to specialised or intensive COPD.. ............................... 934 care unit 940 Medicalhistory 935 Treatment of exacerbations 940 Physicalsigns 935 Exacerbationof COPD: inpatient oxygen therapy.
    [Show full text]
  • Data Driven Investigation of Bispectral Index Algorithm
    www.nature.com/scientificreports OPEN Data Driven Investigation of Bispectral Index Algorithm Hyung-Chul Lee, Ho-Geol Ryu, Yoonsang Park , Soo Bin Yoon, Seong Mi Yang, Hye-Won Oh & Chul-Woo Jung Received: 7 January 2019 Bispectral index (BIS), a useful marker of anaesthetic depth, is calculated by a statistical multivariate Accepted: 9 September 2019 model using nonlinear functions of electroencephalography-based subparameters. However, only Published: xx xx xxxx a portion of the proprietary algorithm has been identifed. We investigated the BIS algorithm using clinical big data and machine learning techniques. Retrospective data from 5,427 patients who underwent BIS monitoring during general anaesthesia were used, of which 80% and 20% were used as training datasets and test datasets, respectively. A histogram of data points was plotted to defne fve BIS ranges representing the depth of anaesthesia. Decision tree analysis was performed to determine the electroencephalography subparameters and their thresholds for classifying fve BIS ranges. Random sample consensus regression analyses were performed using the subparameters to derive multiple linear regression models of BIS calculation in fve BIS ranges. The performance of the decision tree and regression models was externally validated with positive predictive value and median absolute error, respectively. A four-level depth decision tree was built with four subparameters such as burst suppression ratio, power of electromyogram, 95% spectral edge frequency, and relative beta ratio. Positive predictive values were 100%, 80%, 80%, 85% and 89% in the order of increasing BIS in the fve BIS ranges. The average of median absolute errors of regression models was 4.1 as BIS value.
    [Show full text]
  • Authors Conducted an E-Mail Survey of Anesthesiologists in the US in 2010
    Appendix 2: Reference 1 Methods: Authors conducted an e-mail survey of Anesthesiologists in the US in 2010. Results: “Five thousand anesthesiologists were solicited; 615 (12.3%) responses were received. Twenty-four percent of respondents had installed an AIMS, while 13% were either installing a system now or had selected one, and an additional 13% were actively searching. Larger anesthesiology groups with large case loads, urban settings, and government affiliated or academic institutions were more likely to have adopted AIMS. Initial cost was the most frequently cited AIMS barrier. The most commonly cited benefit was more accurate clinical documentation (79%), while unanticipated need for ongoing information technology support (49%) and difficult integration of AIMS with an existing EMR (61%) were the most commonly cited problems.” [Trentman TL, Mueller JT, Ruskin KJ, Noble BN, Doyle CA. Adoption of anesthesia information management systems by US anesthesiologists. J Clin Monit Comput 2011;25:129–35.] Reference 2 Joint Commission Report. 60 [Kohn L, Corrigan JM, Donaldson MS. To Err is Human: Building a Safer Health System. Report from the Committee on Quality of Health Care in America. Washington DC: The Joint Commission journal on quality improvement, 1999:227–34.] Reference 3 Excerpt: “The Department of Health and Human Services (DHHS) released two proposed regulations affecting HIT (www.healthit.hhs.gov). The first, a notice of proposed rule- making (NPRM), describes how hospitals, physicians, and other health care professionals can qualify for billions of dollars of extra Medicare and Medicaid payments through the meaningful use of electronic health records (EHRs). The second, an interim final regulation, describes the standards and certification criteria that those EHRs must meet for their users to collect the payments.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul
    United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul. 9, 1991 54 HYPERBARIC OXYGENATION 4,452,242 6/1984 Bänziger ......................... 128/205.26 APPARATUS AND METHODS 4,467,798 8/1984 Saxon et al. ... ... 128/205.26 4,474,571 10/1984 Lasley ................................... 604/23 75 Inventor: Wallace E. Trammell, Provo, Utah 4,509,513 4/1985 Lasley ....... ... 128/202.12 4,624,656 1 1/1986 Clark et al. ........................... 604/23 73) Assignee: Ballard Medical Products, Midvale, 4,691,.695 9/1987 Birk et al. ............................. 128/38 Utah Appl. No.: 392,169 FOREIGN PATENT DOCUMENTS 21) 317900 12/1919 Fed. Rep. of Germany ... 128/256 22) Filed: Aug. 10, 1989 1 14443 12/1941 United Kingdom ................ 128/248 Related U.S. Application Data OTHER PUBLICATIONS 63 Continuation of Ser. No. 297,351, Jan. 13, 1989, aban TOPOX Literature. doned, which is a continuation of Ser. No. 61,924, Jun. Oxycure Literature. 15, 1987, abandoned, which is a continuation-in-part of B & F Medical Products, Inc. Literature. Ser. No. 865,762, May 22, 1986, abandoned. Primary Examiner-Richard J. Apley (51) Int. Cl. ............................................... A61H 9/00 Assistant Examiner-Linda C. M. Dvorak (52) U.S. Cl. ................................ 128/205.26; 128/30; Attorney, Agent, or Firm-Lynn G. Foster 128/202.12; 128/205.24; 604/23 (58) Field of Search ...................... 128/202. 12, 205.26, 57 ABSTRACT 128/28, 30, 30.2, 38, 40, 402; 600/21; 604/23, A novel hyperbaric oxygenation apparatus, and related 289, 290, 293,304, 305, 308 methods, the apparatus comprising a chamber in the form of a disposable inflatable bag of impervious inex 56 References Cited pensive synthetic resinous material which can be used at U.S.
    [Show full text]
  • Femoral and Sciatic Nerve Blocks for Total Knee Replacement in an Obese Patient with a Previous History of Failed Endotracheal Intubation −A Case Report−
    Anesth Pain Med 2011; 6: 270～274 ￭Case Report￭ Femoral and sciatic nerve blocks for total knee replacement in an obese patient with a previous history of failed endotracheal intubation −A case report− Department of Anesthesiology and Pain Medicine, School of Medicine, Catholic University of Daegu, Daegu, Korea Jong Hae Kim, Woon Seok Roh, Jin Yong Jung, Seok Young Song, Jung Eun Kim, and Baek Jin Kim Peripheral nerve block has frequently been used as an alternative are situations in which spinal or epidural anesthesia cannot be to epidural analgesia for postoperative pain control in patients conducted, such as coagulation disturbances, sepsis, local undergoing total knee replacement. However, there are few reports infection, immune deficiency, severe spinal deformity, severe demonstrating that the combination of femoral and sciatic nerve blocks (FSNBs) can provide adequate analgesia and muscle decompensated hypovolemia and shock. Moreover, factors relaxation during total knee replacement. We experienced a case associated with technically difficult neuraxial blocks influence of successful FSNBs for a total knee replacement in a 66 year-old the anesthesiologist’s decision to perform the procedure [1]. In female patient who had a previous cancelled surgery due to a failed tracheal intubation followed by a difficult mask ventilation for 50 these cases, peripheral nerve block can provide a good solution minutes, 3 days before these blocks. FSNBs were performed with for operations on a lower extremity. The combination of 50 ml of 1.5% mepivacaine because she had conditions precluding femoral and sciatic nerve blocks (FSNBs) has frequently been neuraxial blocks including a long distance from the skin to the used for postoperative pain control after total knee replacement epidural space related to a high body mass index and nonpalpable lumbar spinous processes.
    [Show full text]
  • Oral Anticoagulants
    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
    [Show full text]
  • Efficacy Claims and Subset Analyses in Phase III: Some Thoughts and Examples
    Efficacy Claims and Subset Analyses in Phase III: Some thoughts and examples Kevin J Carroll My personal views, not AZ’s Why do we do them? • Fundamentally, because we can, and we feel compelled to do so. • Yet, we have no agreed framework for the conduct and interpretation of such analyses, nor for their potential implications on product labelling and drug approval. • Of interest to consider the use and utility of subgroup analyses in confirmatory Phase III trials where such analyses are intended: 1. To provide an assessment of internal ‘consistency’ in an trial with an overall positive outcome. 2. By design to formally assess a hypothesis of efficacy in a predefined subset. 3. To salvage a negative trial. 2 The persuasiveness of subset analyses in confirmatory trials PIII trial Not designed to formally Designed to formally assess efficacy in subset assess efficacy in subset Overall result Overall result Co-primary Subset as part positive negative popln, divided of hierarchical alpha formal confirmatory Multiple Post-hoc • Subset exploratory subsets not testing analyses •Subset +ve procedure subsets identified in weakest of identified in advance • label claim even evidence if overall –ve advance • Extremely •Subset +ve difficult to use • label claim • Subset as basis for •Susbet -ve • Looking for defined in approval. • Overall ‘consistency’ response to positive • Grps that data • May be some • Label claim ‘benefit the most • possibly after very limited possible for / least’ regulatory circumstances overall? • Not a matter of rejection where proving efficacy, • How to conditional but obvious respond to approval can potential to such data? be considered impact on with post- labelling approval commitment 3 1.
    [Show full text]
  • Dexmedetomidine During Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair, Randomized Double-Blind Controlled Study Mohamed F
    Korean J Pain 2020;33(1):81-89 https://doi.org/10.3344/kjp.2020.33.1.81 pISSN 2005-9159 eISSN 2093-0569 Original Article Dexmedetomidine during suprazygomatic maxillary nerve block for pediatric cleft palate repair, randomized double-blind controlled study Mohamed F. Mostafa1, Fatma A. Abdel Aal1, Ibrahim Hassan Ali1, Ahmed K. Ibrahim2, and Ragaa Herdan1 1Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Assiut, Egypt 2Department of Public Health, Faculty of Medicine, Assiut University, Assiut, Egypt Received July 26, 2019 Revised December 3, 2019 Background: For children with cleft palates, surgeries at a young age are necessary Accepted December 3, 2019 to reduce feeding or phonation difficulties and reduce complications, especially respiratory tract infections and frequent sinusitis. We hypothesized that dexmedeto- Correspondence midine might prolong the postoperative analgesic duration when added to bupiva- Mohamed F. Mostafa caine during nerve blocks. Department of Anesthesia and Intensive Methods: Eighty patients of 1-5 years old were arbitrarily assigned to two equal Care, Assiut University Hospital, Faculty groups (forty patients each) to receive bilateral suprazygomatic maxillary nerve of Medicine, Assiut University, Assiut blocks. Group A received bilateral 0.2 mL/kg bupivacaine (0.125%; maximum vol- 71515, Egypt Tel: +20-1001123062 ume 4 mL/side). Group B received bilateral 0.2 mL/kg bupivacaine (0.125%) + 0.5 Fax: +20-88-2333327 μg/kg dexmedetomidine (maximum volume 4 mL/side). E-mail: [email protected] Results: The modified children’s hospital of Eastern Ontario pain scale score was significantly lower in group B children after 8 hours of follow-up postoperatively (P < 0.001).
    [Show full text]
  • Moderate Sedation
    MODERATE SEDATION A SELF STUDY GUIDE Part I Self Study Guide Part II ASA Practice Guidelines for Sedation And Analgesia by Non-Anesthesiologists Part III Sedation/Analgesia Policy 1 Introduction Diagnostic and surgical procedures are being performed in a variety of settings throughout the hospital. This self-study program has been developed to increase your awareness and reinforce your understanding of the use of moderate sedation. It includes indications/contraindications for moderate sedation, accepted medications administration guidelines, and monitoring requirements. Part I is dedicated to an overall review of the principles of moderate sedation, Part II includes the American Society of Anesthesiology’s Practice Guidelines For Sedation And Analgesia by Non- Anesthesiologist. Part 3 is a post-test. Completion of this self-study packet includes learning the following material, satisfactory completion of the post-test and returning the post-test to the Medical Staff Office. Completion of this self-study is required to qualify for privileges to administer Moderate Sedation at St. David’s Medical Center. Purpose The purpose of this self-study packet is to increase and reinforce your knowledge of responsibilities and guidelines associated with the care of individuals requiring moderate sedation. On completion of this self-study program, you should be able to: 1. Recognize indications and contraindication for moderate sedation. 2. State appropriate monitoring techniques and requirements for patients undergoing moderate sedation. 3. Identify medications frequently used for moderate sedation, administration guidelines, and potential complications/side-effects. 4. Evaluate and manage expected and unexpected outcomes of moderate sedation Part I Definition Conscious Sedation more accurately termed Sedation/Analgesia or Moderate Sedation describes a state that allows patients to tolerate unpleasant procedures while maintaining adequate cardiorespiratory function and the ability to respond purposefully to verbal commands and tactile stimulation.
    [Show full text]